Table 1. CD133 expression analysis by immunohistochemistry.

		CD133+ cases: ab5558, AC133 (n)
Tumour type	Total cases (n)	1–2+	2–3+	3–4+	Total CD133+ cases: ab5558, AC133 (%)
Primary tumours
Gastric adenocarcinomas	60	25, 22	2, 6	6, 0	55, 47
Pancreatic ductal adenocarcinomas	31	13, 15	8, 2	0, 0	68, 55
Kidney and urothelial carcinomas	29	6, 1	5, 2	0, 0	38, 10
Intrahepatic cholangiocarcinomas	12	7, 8	1, 0	0, 0	67, 67
Prostatic adenocarcinomas	39	6, 2	2, 2	0, 0	20, 5
Metastatic tumours
Livera	30	7, 10	6, 4	1, 5	47, 63
Gastric	20	6, 6	1, 4	3, 0	50, 50

CD133 expression in solid carcinomas was analysed using tissue microarrays and anti-CD133 MAbs, ab5558 and AC133 and then scored based on the intensity of staining (1–4+, see Figure 1(A–C).

^aPredominantly colonic in origin.